U.S. Markets closed
LISTEN

Schultz: Businesses need to do more to help people

Yahoo Finance's Julia La Roche sits down with executive chairman and former CEO of Starbucks Howard Schultz

Epizyme, Inc. (EPZM)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
16.95-1.75 (-9.36%)
At close: 4:00PM EDT
People also watch
OMEDXLRNAGIOKPTIENTA

Epizyme, Inc.

400 Technology Square
4th Floor
Cambridge, MA 02139
United States
617-229-5872
http://www.epizyme.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees112

Key Executives

NameTitlePayExercisedAge
Mr. Robert B. Bazemore Jr.Chief Exec. Officer, Pres, Sec. and Director786.24kN/A49
Dr. H. Robert Horvitz Ph.D., M.D.Co-Founder and Chairman of the Scientific Advisory BoardN/AN/AN/A
Dr. Yi Zhang Ph.D.Scientific Co-Founder and Member of The Scientific Advisory BoardN/AN/AN/A
Mr. Matthew E. RosChief Operating OfficerN/AN/A50
Dr. Michael Boretti Ph.D.VP of Bus. Devel.N/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Epizyme, Inc., a clinical stage biopharmaceutical company, discovers and develops novel epigenetic therapies for patients with cancer and other diseases in the United States. Its product candidates include tazemetostat, an inhibitor of the EZH2 HMT, which is in five-arm Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma; Phase I dose-escalation and expansion study for children with INI1-negative solid tumors; Phase II and Ib clinical trials for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL); Phase Ib/II clinical trial for elderly patients with DLBCL; and Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function, as well as Phase II clinical trial in adult patients with ovarian cancer. The company is also developing additional programs, such as pinometostat, an intravenously administered small molecule inhibitor of DOT1L for the treatment of acute leukemias; and PRMT5 inhibitor that is in Phase I clinical trial for patients with solid tumors and NHL. It has collaboration agreements with Celgene Corporation, Celgene RIVOT Ltd., Genentech Inc., Glaxo Group Limited, and US Oncology Research, as well as with Roche Molecular Systems, Inc., Eisai Co. Ltd., and Lymphoma Study Association. Epizyme, Inc. was founded in 2007 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Epizyme, Inc.’s ISS Governance QualityScore as of September 1, 2017 is 8. The pillar scores are Audit: 1; Board: 8; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.